|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/23 Y-mAbs Therapeutics, Inc. 10-K 12/31/22 106:10M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.63M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 50K
3: EX-10.41 Material Contract HTML 39K
4: EX-10.42 Material Contract HTML 325K
5: EX-21.1 Subsidiaries List HTML 28K
6: EX-23 Consent of Expert or Counsel HTML 28K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 36K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
16: R1 Document and Entity Information HTML 97K
17: R2 Consolidated Balance Sheets HTML 123K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
19: R4 Consolidated Statements of Net Income (Loss) and HTML 98K
Comprehensive Income (Loss)
20: R5 Consolidated Statements of Changes in HTML 79K
Stockholders' Equity
21: R6 Consolidated Statements of Cash Flows HTML 103K
22: R7 Organization and Description of Business HTML 32K
23: R8 Basis of Presentation HTML 36K
24: R9 Summary of Significant Accounting Policies HTML 115K
25: R10 Product Revenue HTML 62K
26: R11 Net Loss Per Share HTML 42K
27: R12 Inventories HTML 60K
28: R13 Intangible Assets, Net HTML 32K
29: R14 Accrued Liabilities HTML 46K
30: R15 License Agreements and Commitments HTML 164K
31: R16 Stockholders' Equity HTML 41K
32: R17 Share-Based Compensation HTML 110K
33: R18 Related Party Transactions HTML 32K
34: R19 Income Taxes HTML 126K
35: R20 Other Benefits HTML 31K
36: R21 Gain From Sale of Priority Review Voucher HTML 31K
37: R22 Subsequent Events HTML 32K
38: R23 Summary of Significant Accounting Policies HTML 164K
(Policies)
39: R24 Summary of Significant Accounting Policies HTML 74K
(Tables)
40: R25 Product Revenue (Tables) HTML 56K
41: R26 Net Loss Per Share (Tables) HTML 40K
42: R27 Inventories (Tables) HTML 59K
43: R28 Accrued Liabilities (Tables) HTML 46K
44: R29 License Agreements and Commitments (Tables) HTML 132K
45: R30 Share-Based Compensation (Tables) HTML 101K
46: R31 Income Taxes (Tables) HTML 129K
47: R32 BASIS OF PRESENTATION - Accumulated deficit HTML 32K
(Details)
48: R33 BASIS OF PRESENTATION - Public offering (Details) HTML 41K
49: R34 BASIS OF PRESENTATION - Cash and cash equivalents HTML 31K
(Details)
50: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 36K
Concentration of Credit Risk (Details)
51: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Inventory (Details)
52: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 46K
Value Measurement (Details)
53: R38 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Operating Leases (Details)
54: R39 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Revenue Recognition - Product revenue (Details)
55: R40 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 65K
Revenue Recognition - License revenue (Details)
56: R41 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Segment (Details)
57: R42 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 44K
Property and Equipment (Details)
58: R43 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 30K
Income Taxes (Details)
59: R44 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 31K
Research and development (Details)
60: R45 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other HTML 33K
policies (Details)
61: R46 PRODUCT REVENUE - Disaggregation (Details) HTML 41K
62: R47 PRODUCT REVENUE - Discounts and Allowances HTML 71K
(Details)
63: R48 PRODUCT REVENUE - Concentrations (Details) HTML 44K
64: R49 NET LOSS PER SHARE - Basic and diluted (Details) HTML 56K
65: R50 NET LOSS PER SHARE - Anti-dilutive securities HTML 30K
(Details)
66: R51 Inventories (Details) HTML 51K
67: R52 Intangible Assets, Net (Details) HTML 68K
68: R53 Accrued Liabilities (Details) HTML 42K
69: R54 LICENSE AGREEMENTS AND COMMITMENTS - MSK License HTML 57K
(Details)
70: R55 LICENSE AGREEMENTS AND COMMITMENTS - LCD33 License HTML 44K
(Details)
71: R56 LICENSE AGREEMENTS AND COMMITMENTS - MabVax/MSK HTML 36K
License (Details)
72: R57 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 38K
Agreement (Details)
73: R58 LICENSE AGREEMENTS AND COMMITMENTS - Summary of HTML 69K
Significant Agreements and Commitments (Details)
74: R59 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 47K
agreements (Details)
75: R60 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 68K
agreements (Details)
76: R61 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 37K
(Details)
77: R62 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 46K
maturities (Details)
78: R63 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 33K
and discount rate (Details)
79: R64 LICENSE AGREEMENTS AND COMMITMENTS - Severance HTML 37K
Related Benefits (Details)
80: R65 LICENSE AGREEMENTS AND COMMITMENTS - Legal matters HTML 35K
(Details)
81: R66 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 47K
Preferred Stock (Details)
82: R67 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 83K
non-employees (Details)
83: R68 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 42K
(Details)
84: R69 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 37K
85: R70 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 54K
86: R71 SHARE-BASED COMPENSATION - Stock-based HTML 40K
compensation expense - Options (Details)
87: R72 SHARE-BASED COMPENSATION - Stock Option Valuation HTML 37K
(Details)
88: R73 SHARE-BASED COMPENSATION - Stock option activity HTML 67K
(Details)
89: R74 SHARE-BASED COMPENSATION - Stock option grants HTML 58K
(Details)
90: R75 SHARE-BASED COMPENSATION - Stock option HTML 35K
unrecognized compensation (Details)
91: R76 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 67K
Activity (Details)
92: R77 Related Party Transactions (Details) HTML 47K
93: R78 INCOME TAXES - Loss before income taxes (Details) HTML 44K
94: R79 INCOME TAXES - Current and deferred income taxes HTML 45K
(Details)
95: R80 INCOME TAXES - Reconciliation of Income Taxes HTML 57K
(Details)
96: R81 INCOME TAXES - Deferred assets (Liabilities) HTML 58K
(Details)
97: R82 INCOME TAXES - Net Operating Loss Carryforwards HTML 41K
(Details)
98: R83 INCOME TAXES - Unrecognized tax benefits (Details) HTML 35K
99: R84 Other Benefits (Details) HTML 35K
100: R85 Gain From Sale of Priority Review Voucher HTML 40K
(Details)
101: R86 Subsequent Events (Details) HTML 39K
104: XML IDEA XML File -- Filing Summary XML 193K
102: XML XBRL Instance -- ymab-20221231x10k_htm XML 1.92M
103: EXCEL IDEA Workbook of Financial Reports XLSX 181K
12: EX-101.CAL XBRL Calculations -- ymab-20221231_cal XML 178K
13: EX-101.DEF XBRL Definitions -- ymab-20221231_def XML 793K
14: EX-101.LAB XBRL Labels -- ymab-20221231_lab XML 1.51M
15: EX-101.PRE XBRL Presentations -- ymab-20221231_pre XML 1.24M
11: EX-101.SCH XBRL Schema -- ymab-20221231 XSD 244K
105: JSON XBRL Instance as JSON Data -- MetaLinks 469± 746K
106: ZIP XBRL Zipped Folder -- 0001558370-23-005073-xbrl Zip 974K
EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Y-mAbs Therapeutics, Inc. (the “Company”) hereby certifies, to his knowledge, that:
| (i) | the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
| (ii) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| |
Dated: March 30, 2023 | /s/ Thomas Gad |
| Name: Thomas Gad |
| Title: Founder, Chairman, President, Interim Chief Executive Officer and Head of Business Development and Strategy |
| (Principal Executive Officer) |
1
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/23 | 8-K | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA 5/08/23 Y-mAbs Therapeutics, Inc. 10-Q 3/31/23 85:7.4M Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. S-8 3/30/23 4:168K Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. S-3 5:975K Toppan Merrill Bridge/FA |